Trends in RA patients’ adherence to subcutaneous anti-TNF therapies and costs

References

• Harris Jr ED. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. Epidemiol Rev 1981;3:27-44
   PubMed Web of Science ®Google Scholar
• Allaire SL, Prashker M, Meenan R. The costs of rheumatoid arthritis. Pharmacoeconomics 1994;6:513-22
   PubMed Web of Science ®Google Scholar
• Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39:28-33
   PubMed Web of Science ®Google Scholar
• Combe B. Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009;23:59-69
   Google Scholar
• Grijalva CG, Chung CP, Arbogast PG, et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007;45:S66-76
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Saxne T, Nilsson JA, et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174
   PubMed Web of Science ®Google Scholar
• Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006;19:47-53
   PubMedGoogle Scholar
• Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50
   Google Scholar
• Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46
   PubMed Web of Science ®Google Scholar
• van den Bemt BJ, van Lankveld WG. How can we improve adherence to therapy by patients with rheumatoid arthritis? Nat Clin Pract Rheumatol 2007;3:681
   PubMedGoogle Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-74
   PubMed Web of Science ®Google Scholar
• Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum2009;38:396-402
   Google Scholar
• Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress. Available at: http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf [Last accessed 26 August 2008]
   Google Scholar
• Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project. Comorbidity Software. Available at: http://www.hcupus.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp [Last accessed 26 August 2008]
   Google Scholar
• Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
   PubMed Web of Science ®Google Scholar
• Rizzo JA, Simmons R. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446-57
   PubMed Web of Science ®Google Scholar
• Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9:S136-43
   PubMed Web of Science ®Google Scholar
• Rosenbaum P, Rubin DB. The central role of the propensity score matching in observational studies for causal effects. Biometrika 1983;70:41-55
   Web of Science ®Google Scholar
• Dehejia RH, Wahba S. Propensity score-matching methods for nonexperimental causal studies. Rev Econ Stat 2002;84:151-61
   Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporates the propensity score. American Statistician 1985;39:33-8
   Web of Science ®Google Scholar
• Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999;18:153-71
   PubMed Web of Science ®Google Scholar
• Rubin DB, Thomas N. Combining propensity score matching with additional adjustments for prognostic covariates. J Am Stat Assoc 2001;95:573-85
   Web of Science ®Google Scholar
• Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999;18:153-71
   PubMed Web of Science ®Google Scholar
• Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-94
   PubMed Web of Science ®Google Scholar
• Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman and Hall/CRC, 1993
   Google Scholar
• StataCorp. 2007. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP
   Google Scholar
• Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001;10:601-15
   PubMed Web of Science ®Google Scholar
• Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. Pharmacoeconomics 1999;15:217-28
   PubMed Web of Science ®Google Scholar
• Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. Am J Manag Care 2005;11:S459-64
   PubMed Web of Science ®Google Scholar
• Galindo-Rodriguez G, Avina-Zubieta JA, Russell AS, et al. Disappointing long term results with disease modifying antirheumatic drugs. A practice based study. J Rheumatol 1999;26:2337-43
   Google Scholar
• Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995;9:619-32
   PubMed Web of Science ®Google Scholar
• Maetzel A, Wong A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs. Rheumatology (Oxford) 2000;39:975-8136
   PubMed Web of Science ®Google Scholar